NCT04482569View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 10, 2020

Primary Completion Date

February 28, 2021

Study Completion Date

September 30, 2021

Conditions
Bacterial Infections
Interventions
DRUG

XNW4107

Single or multiple dose ascending study for XNW4107 alone or multiple dose study of XNW4107 in combination with imipenem/cilastatin

Trial Locations (1)

21201

Pharmaron CPC, Baltimore

Sponsors
All Listed Sponsors
lead

Evopoint Biosciences Inc.

INDUSTRY